What does Crescent Biopharma do?
Crescent Biopharma, Inc. is a clinical-stage oncology company whose ordinary shares trade on the Nasdaq Capital Market under the ticker CBIO. The company is incorporated in the Cayman Islands and operates from Waltham, Massachusetts. Its strategy is unusually focused: build a portfolio around validated cancer targets, combine complementary therapeutic modalities, and move programs rapidly into trials rather than creating a broad discovery organization. The official company overview describes a vision of creating a leading oncology company around next-wave therapies for solid tumors.
What is the portfolio built to accomplish?
The lead asset, CR-001, is a tetravalent bispecific antibody designed to block both PD-1 and VEGF. CR-002 is a PD-L1-targeted antibody-drug conjugate, or ADC, carrying a topoisomerase inhibitor payload. CR-003, also known as SKB105, is an ITGB6-targeted ADC being studied in China by Kelun-Biotech, while Crescent holds rights outside Greater China. Together, the programs create a deliberate combination thesis: CR-001 may function as an immuno-oncology backbone, while the ADCs deliver cytotoxic payloads to tumor-associated targets.
| Identity item | Current fact | Why it matters |
|---|---|---|
| Listing | Nasdaq Capital Market, CBIO | Public equity is the primary financing channel for a pre-revenue development company. |
| Sector | Clinical-stage biotechnology / oncology | Value depends mainly on clinical evidence, regulatory progress, capital needs, and intellectual-property durability. |
| Customers today | No commercial product customers; one licensing counterparty generated reported revenue | Current revenue is collaboration accounting, not recurring product demand. |
| Geographic model | Global development, with Greater China rights split through Kelun | Partnership data can accelerate learning, but territorial rights and economics are shared. |
Crescent is best analyzed as a financed clinical portfolio. Program quality, trial timing, and cash runway matter more than conventional revenue growth.
How does Crescent Biopharma make money before product approval?
Crescent has no approved medicine or recurring product sales. Current economics come from licensing, while cash outflows fund research, manufacturing, trials, personnel, and public-company costs. Q1 2026 license revenue related to Kelun’s upfront payment for Greater China rights to CR-001; it was not product demand.
What are the principal revenue pathways?
Under the CR-001 arrangement, Kelun paid $20.0 million upfront and may pay up to $30.0 million of development and regulatory milestones, plus tiered royalties on Greater China net sales. Crescent separately paid for ex-Greater China rights to CR-003. The 2025 Form 10-K shows why licensing events can move revenue, research expense, and cash flow sharply.
Which pipeline programs matter most?
All three programs address solid tumors, but they play different strategic roles. CR-001 is the central platform asset because it can be tested alone, with chemotherapy, and with ADCs. CR-002 provides a wholly controlled ADC program around PD-L1. CR-003 adds a clinically advancing ADC sourced from Kelun and offers external China data before Crescent launches development elsewhere. The company’s official pipeline emphasizes this multi-modality design.
How do stage, ownership, and timing differ?
| Program | Mechanism | Development position | Key stated milestone |
|---|---|---|---|
| CR-001 | Tetravalent PD-1 and VEGF blockade | ASCEND Phase 1/2 in advanced solid tumors; Greater China program partnered | Proof-of-concept data targeted for Q1 2027; chemotherapy data targeted for mid-2027 |
| CR-002 | PD-L1-targeted topoisomerase inhibitor ADC | Clinic entry planned after IND work | Phase 1/2 start targeted for H2 2026; proof-of-concept targeted for H2 2027 |
| CR-003 / SKB105 | ITGB6-targeted topoisomerase inhibitor ADC | Kelun Phase 1/2 ongoing in China | Proof-of-concept data targeted for Q1 2027; CR-001 combination targeted to begin in H1 2027 |
Where did Q1 2026 research spending go?
What does Crescent Biopharma’s latest reported period show?
The latest complete income statement covers the quarter ended March 31, 2026; preliminary June cash was disclosed before the July financing. Clinical expansion and public-company infrastructure raised expenses while licensing revenue remained small. The first-quarter earnings release and Form 10-Q confirm ongoing ASCEND enrollment and rising development spending.
How did the quarter compare with the prior-year period?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| License revenue | $1.039M | $0 | Recognition related to the Kelun CR-001 collaboration, not product sales. |
| R&D expense | $17.903M | $10.627M | Increase of $7.276M as clinical and personnel activity expanded. |
| G&A expense | $7.865M | $3.597M | Higher personnel, professional-service, facilities, and patent costs. |
| Operating loss | $24.729M | $14.224M | The expense base grew faster than collaboration revenue. |
| Net loss | $23.283M | $15.148M | Interest income of $1.446M partly offset the operating loss. |
| Net loss per share | $0.70 | $19.63 | Per-share comparisons are distorted by the reverse merger and changed share count. |
How quickly did cash change before the July offering?
Which turning points shaped Crescent’s current strategy?
Crescent’s short history was shaped by financing, program licenses, a public-company merger, and the Kelun collaboration. Each event changed the asset set, capital access, or timing of clinical evidence.
-
September 2024Pre-merger Crescent was established and raised a $4.0M seed financing led by Fairmount, creating the initial corporate platform.
-
October 2024The company raised $37.5M through convertible notes and agreed to merge with GlycoMimetics, pairing the private pipeline with a listed entity.
-
April 2025Crescent exercised and formalized rights to CR-001 from Paragon, making the PD-1 × VEGF bispecific its lead program.
-
June 2025The merger closed, the company adopted the Crescent name, and the group became a Cayman Islands issuer trading under CBIO. Net proceeds from the pre-closing financing were approximately $142.3M.
-
November 2025The CR-002 license was signed, adding a PD-L1 ADC and a future $5.0M milestone obligation upon first Phase 1 dosing.
-
December 2025The Kelun transactions added ex-Greater China rights to CR-003 and licensed Greater China rights to CR-001; a private placement produced approximately $171.9M of net proceeds.
-
January–February 2026The FDA cleared the CR-001 IND and the first patient was dosed in ASCEND, moving Crescent from a preclinical thesis to a clinical execution story.
-
July 2026The public offering added approximately $143.7M of gross capital after Q1 guidance had already indicated funding into 2028.
What strategic pattern connects these events?
The pattern is speed through external assets and financing. Crescent licensed programs, partnered territorial development, and used public equity to fund parallel trials. This compresses the path to data but increases dependence on contracts, counterparties, manufacturers, and capital markets. The merger closing filing shows how the listing became the financing architecture for the current plan.
What gives Crescent an edge—and where is the moat fragile?
Crescent’s potential advantage is not established market power. It is a portfolio design that combines validated targets, differentiated molecular formats, clinical speed, and cross-program combination options. CR-001 seeks to join immune-checkpoint inhibition with VEGF blockade in one molecule. CR-002 and CR-003 add tumor-targeted payload delivery. If the programs show complementary activity, Crescent could build a coherent regimen portfolio rather than three unrelated assets.
How strong are the underlying strategic resources?
The largest fragility is intellectual-property dependence. Crescent does not own issued patents and relies materially on rights licensed from Paragon and Kelun. Termination, milestone obligations, royalties, patent challenges, or weak claims could reduce economic value. The portfolio is organized and potentially valuable, but clinical outcomes have not yet proven it rare or difficult to imitate.
Who defines the competitive benchmark?
Approved PD-1 therapies set a high efficacy bar, while PD-1/VEGF bispecific programs validate the category and intensify rivalry. ADC competitors also pursue validated targets, optimized linkers, tolerable payloads, and scarce trial capacity. Crescent can be focused and fast, but larger rivals have manufacturing, regulatory, and commercial scale. It must win through data quality and development choices.
How strong is the balance sheet and capital-allocation model?
At March 31, 2026, Crescent reported $189.2 million of cash, $195.6 million of current assets, $14.2 million of current liabilities, and $183.8 million of equity. A current ratio near 13.8× indicates strong near-term liquidity, but recurring losses and expanding trials still consume capital.
What does annual cash use reveal?
In 2025, operating cash use was $71.5 million and investing cash use was $72.9 million, largely reflecting a research license. Q1 2026 operating cash use was about $8.9 million. License payments make burn lumpy, so simple quarterly extrapolation can mislead.
| Capital item | Period / amount | Analytical meaning |
|---|---|---|
| Cash and equivalents | $213.2M at Dec. 31, 2025; $189.2M at Mar. 31, 2026; $171.6M preliminary at Jun. 30, 2026 | Pre-offering cash declined as programs and infrastructure advanced. |
| 2025 operating cash use | $71.5M | Recurring development and organizational spending before commercialization. |
| 2025 investing cash use | $72.9M | Mostly the CR-003 license purchase, illustrating transaction-driven capital intensity. |
| December 2025 private placement | $185.0M gross; about $171.9M net | Funded parallel programs but expanded the share base. |
| July 2026 public offering | $143.7M gross | Added capital after the company had guided that March 2026 cash could fund operations into 2028. |
| Dividends / buybacks | None expected at this stage | Capital is retained for R&D; shareholder return depends on asset value creation, not distributions. |
Who owns Crescent stock and why does governance matter?
Ownership is institutionally concentrated, with a strategically influential Fairmount group and several specialist biotechnology investors. The April 2026 proxy reported Fairmount, FMR, BVF, Venrock, ForGrowth, Vestal Point, and 1 Globe Capital as major holders. Directors and executive officers as a group held 24.84%, but that group total overlaps with affiliated holdings.
How does the share structure affect control?
| Holder or governance item | Officially reported position | Source period | Why it matters |
|---|---|---|---|
| Fairmount group | 5,643,482 ordinary-share equivalents; 18.52%; all 2,890 Series A preferred shares | Proxy, Apr. 7, 2026 | Combines economic ownership, board relationships, and special preferred-share voting rights. |
| FMR affiliates | 4,133,514 shares; 14.99% | Proxy, Apr. 7, 2026 | Large professional investor ownership can influence governance through voting and engagement. |
| BVF and Venrock | 9.98% and 9.49%, respectively | Proxy, Apr. 7, 2026 | Specialist biotechnology investors can support financings but may also focus closely on clinical milestones. |
| Ordinary shares | One vote per share | 2026 proxy | Economic and voting rights are generally aligned for ordinary holders. |
| Series A preferred | 2,890 shares, convertible at 1,000 ordinary shares each; special director-election rights | 2026 proxy | Creates specific influence over designated board seats beyond ordinary one-share-one-vote mechanics. |
| Post-offering Fairmount update | 6,593,385 beneficial shares; 16.50% of 39,960,923 ordinary shares outstanding | Schedule 13D/A, Jul. 20, 2026 | Fairmount remained a major holder after buying in the July offering, even as dilution lowered its percentage. |
The ownership figures and special voting mechanics are detailed in the 2026 proxy statement. The latest Fairmount position appears in the July 2026 Schedule 13D amendment.
What opportunities and risks could change the story?
Crescent sits in the high-opportunity, high-uncertainty quadrant of oncology development. Several catalysts arrive in a concentrated window, but the programs share partners, financing needs, and one small organization. A central safety or efficacy problem could affect multiple combinations.
Which catalysts offer the greatest upside?
What risks are most financially material?
| Risk | Financial or strategic transmission | What to monitor |
|---|---|---|
| Clinical efficacy or safety failure | Can impair an asset, reduce partnership value, trigger restructuring, and shorten effective runway. | Dose-limiting toxicities, discontinuations, response rate, response duration, and biomarker consistency. |
| Crowded PD-(L)1/VEGF and ADC competition | Raises the differentiation bar and can make a merely active drug commercially insufficient. | Head-to-head benchmarks, trial design, patient selection, dosing convenience, and safety profile. |
| Licensed intellectual property | Termination, weak protection, royalties, or milestone burdens can reduce net program economics. | Patent prosecution, license compliance, validity challenges, and disclosed milestone payments. |
| Manufacturing and external vendors | Delays or quality failures can postpone enrollment and waste drug-supply investment. | Clinical supply availability, CMO capacity, comparability work, and trial-site activation. |
| Financing and dilution | New equity preserves programs but reduces existing holders’ percentage ownership. | Cash runway, planned cohort count, milestone obligations, option and warrant overhang, and financing terms. |
| Partner and territorial dependence | Kelun data and execution affect CR-001 and CR-003 timelines, while economics are divided by geography. | China enrollment, data transfer, manufacturing coordination, and collaboration compliance. |
Why does Crescent matter for valuation, and what should readers monitor?
Crescent requires a probability-adjusted model rather than a smooth revenue DCF. Estimate each program’s chance of reaching clinical and regulatory gates, model patients and pricing only after defining a plausible product profile, subtract development and commercialization costs, include royalties and milestones, and discount for time and risk. Cash is both value and the fuel consumed to create evidence.
Which operating indicators belong in a research model?
| Valuation driver | Current anchor | Model implication |
|---|---|---|
| CR-001 probability of success | Phase 1/2 ASCEND; proof-of-concept targeted for Q1 2027 | The largest probability-weighted asset should be sensitized to safety, response quality, and development path. |
| ADC portfolio probability | CR-002 planned clinic entry; CR-003 Phase 1/2 ongoing in China | Programs should be modeled separately because stage, target, rights, and evidence sources differ. |
| Cash and financing | $171.6M preliminary cash at Jun. 30, 2026, followed by $143.7M gross offering proceeds | Use net proceeds, future burn, and dilution; do not simply add gross proceeds to cash as a reported balance. |
| License economics | Kelun and Paragon milestones, royalties, and territorial rights | Value the company’s retained geography and deduct contractual payments from asset-level cash flows. |
| Terminal economics | No approved products or commercial infrastructure | Long-term margins, launch timing, and selling costs require wide scenarios rather than a single point estimate. |
| Share count | 39,960,923 ordinary shares outstanding after the July offering, plus warrants, preferred conversion, options, and RSUs | Per-share value must use a fully diluted share count consistent with security terms and ownership limits. |
What should students, researchers, and investors watch next?
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
